Targeting key mediators of allergic inflammation such as IgE, IL-5, and IL-4/IL-13 constitutes a novel therapy in patients suffering from CRSwNP and their applicability to patients with CRSwNP refractory to standard treatment is underway [76]. This evidence concerns the gene IGHE and chronic rhinosinusitis with nasal polyps.